Shopping Cart
Remove All
Your shopping cart is currently empty
FTX-6746 is an orally active and selective PPARG reverse inhibitor with anticancer activity. It can be used in research on urothelial carcinoma.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $199 | - | In Stock |
| Description | FTX-6746 is an orally active and selective PPARG reverse inhibitor with anticancer activity. It can be used in research on urothelial carcinoma. |
| In vivo | In mouse UMUC9 or HT1197 xenograft models, FTX-6746 significantly inhibited tumor growth by oral administration (doses of 3-60 mg/kg twice daily for 21 days). [1] |
| Synonyms | FX909, FX 909, FTX6746 |
| Molecular Weight | 316.69 |
| Formula | C16H7ClF2N2O |
| Cas No. | 2829349-96-2 |
| Smiles | N#CC=1C=CC(Cl)=C(C1)C2=CC(=O)C=3C(F)=CC(F)=CC3N2 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (94.73 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.32 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.